Abstract
Developed for bypass surgery, tissue-engineered vascular grafts should remain passable after implantation and have high rate of endothelialization to ensure long-term patency, atrombogenicity and biocompatibility. This study was aimed at assessing the long-term patency of polyhydroxybutyrate/valerate (PHBV)/polycaprolactone (PCL) vascular grafts modified by pro-angiogenic factors and athrombogenic drug coating in a large laboratory animal model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have